Abstract 235TiP
Background
Hamlet.rt (Heuristics, Algorithms and Machine Learning: Evaluation & Testing in Radiation Therapy) is a multi-centre study exploring the role of machine learning in predicting response and toxicity in patients receiving radical radiotherapy for non-small cell lung cancer (NSCLC), Head and Neck Cancer (H&N Cancer) and Prostate cancer. Hamlet.rt Trans is a translational sub-study that leverages the infrastructure of Cancer Research UK RadNet Cambridge to evaluate multiple liquid biomarkers of radiation response. This study aims to investigate biomarkers of treatment response in patients with lung and head and neck cancers and markers of treatment toxicity in patients with prostate cancer.
Trial design
HAMLET.trans is a translational biosampling study of patients undergoing radical radiotherapy for NSCLC, H&N cancer or prostate cancer. Venous samples for ctDNA analysis and senescence-related profiling are collected together with dried blood spot samples before chemotherapy and radiotherapy at multiple time points during radiotherapy and post-treatment. Urine is collected from patients with prostate cancer. Patients are completing toxicity questionnaires during and after radiotherapy. Delivery dose per fraction is assessed based on imaging just before radiotherapy delivery. The trial aims to recruit at least 20 patients per arm. Patient samples are analysed for tumor-specific mutation, methylation profiling of cfDNA as well as cytokine assays to establish markers or response and toxicity and identify optimal sample timings for future studies. Blood spots are analysed for ctDNA tumour content to establish a less invasive way of frequent sampling on therapy. The results of HAMLET.trans will inform ongoing translational work.
Clinical trial identification
NCT04060706.
Editorial acknowledgement
Legal entity responsible for the study
Cambridge Cancer Trials Centre.
Funding
Cancer Research UK and the Medical Research Council UK.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
273P - A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2- early breast cancer (EBC): Final analysis from EMBER-2
Presenter: Patrick Neven
Session: Poster session 02
274P - Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): Analyses from the monarchE study
Presenter: Joyce O'Shaughnessy
Session: Poster session 02
275P - Clinical and molecular impact of neoadjuvant chemotherapy (NACT) or endocrine therapy (NET) on hormone receptor positive (HR+)/HER2-negative (-) breast cancer (BC)
Presenter: Francesco Schettini
Session: Poster session 02
276P - Development and external validation of an artificial intelligence (AI)-based machine learning model (ML) for predicting pathological complete response (pCR) in hormone-receptor (HoR)-positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT)
Presenter: Luca Mastrantoni
Session: Poster session 02
277P - Fat body mass independently predicts incident vertebral fractures in breast cancer patients given adjuvant aromatase inhibitor therapy and denosumab
Presenter: Greta Schivardi
Session: Poster session 02
278P - Association between tamoxifen and endoxifen plasma levels and clotting proteins in patients with primary breast cancer
Presenter: Daan van Dorst
Session: Poster session 02
279P - Early changes in bone turnover biomarkers during AI therapy are related to loss bone mineral density, data of the B-ABLE cohort
Presenter: Tamara Martos Cardenas
Session: Poster session 02
280P - Adjuvant aromatase inhibitors in patients with PIK3CA mutation early breast cancer
Presenter: Kristin Reinhardt
Session: Poster session 02
282P - Analysis of Prosigna in hormone receptor-positive early-stage breast cancer cohort after 8 years of experience at a single institution
Presenter: DANIEL MORCHÓN ARAUJO
Session: Poster session 02